GSK announces submission to U.S. regulatory authorities for Promactaâ„¢ (eltrombopag) for severe aplastic anaemia

[at noodls] – GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promactaâ„¢ (eltrombopag) for the treatment of … more

View todays social media effects on GSK

View the latest stocks trending across Twitter. Click to view dashboard

See who GlaxoSmithKline is hiring next, click here to view